Gene · 4926
Papers2,697
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,697
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer. | Biomedicines | 2023 | 36831075 | PubTator, text mining | PubMed |
| Ultra-Rare Variants Identify Biological Pathways and Candidate Genes in the Pathobiology of Non-Syndromic Cleft Palate Only. | Biomolecules | 2023 | 36830605 | PubTator, text mining | PubMed |
| Research progress on molecular biomarkers of acute myeloid leukemia. | Front Oncol | 2023 | 36824144 | PubTator, text mining | PubMed |
| AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation. | Life Sci Alliance | 2023 | 36797043 | PubTator, text mining | PubMed |
| Importin α/β promote Kif18B microtubule association and enhance microtubule destabilization activity. | Mol Biol Cell | 2023 | 36790918 | PubTator, text mining | PubMed |
| Diagnostic Performance of Biomarkers for Bladder Cancer Detection Suitable for Community and Primary Care Settings: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2023 | 36765672 | PubTator, text mining | PubMed |
| A Novel Methylation Marker NRN1 plus TERT and FGFR3 Mutation Using Urine Sediment Enables the Detection of Urothelial Bladder Carcinoma. | Cancers (Basel) | 2023 | 36765573 | PubTator, text mining | PubMed |
| Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine. | Front Immunol | 2023 | 36761744 | PubTator, text mining | PubMed |
| Mutation-class dependent signatures outweigh disease-associated processes in cystic fibrosis cells. | Cell Biosci | 2023 | 36759923 | PubTator, text mining | PubMed |
| Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer. | JCI Insight | 2023 | 36757813 | PubTator, text mining | PubMed |
| The Frequency of Immunofluorescence Antinuclear Antibody Patterns and Extractable Nuclear Antigen: Experience From a Large Laboratory in Pakistan. | Cureus | 2023 | 36751152 | PubTator, text mining | PubMed |
| Evaluation of a biosensor-based graphene oxide-DNA nanohybrid for lung cancer. | RSC Adv | 2023 | 36741187 | PubTator, text mining | PubMed |
| Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma. | Mol Cancer | 2023 | 36739413 | PubTator, text mining | PubMed |
| Current methods facilitating diagnosis of upper tract urothelial carcinoma: a comprehensive literature review. | Curr Opin Urol | 2023 | 36727755 | PubTator, text mining | PubMed |
| A nucleotide binding-independent role for γ-tubulin in microtubule capping and cell division. | J Cell Biol | 2023 | 36695784 | PubTator, text mining | PubMed |
| (Nano)platforms in bladder cancer therapy: Challenges and opportunities. | Bioeng Transl Med | 2023 | 36684065 | PubTator, text mining | PubMed |
| Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1. | Viruses | 2023 | 36680249 | PubTator, text mining | PubMed |
| Relative Risk of Bladder and Kidney Cancer in Lynch Syndrome: Systematic Review and Meta-Analysis. | Cancers (Basel) | 2023 | 36672455 | PubTator, text mining | PubMed |
| Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer. | Biosensors (Basel) | 2023 | 36671940 | PubTator, text mining | PubMed |
| Recent Trends in Metal Nanoparticles Decorated 2D Materials for Electrochemical Biomarker Detection. | Biosensors (Basel) | 2023 | 36671926 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4926/papers?page=13